Association of WWOX Rs9926344 Polymorphism with Poor Prognosis of Hepatocellular Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Apr 21

PMID 29675105

Citations 5

Authors

Wanyong Chen

Chenhao Zhou

Wentao Zhang

Manar Atyah

Yirui Yin

Lei Guo

Weiguo Tang

Qiongzhu Dong

Qinghai Ye

Ning Ren

Affiliations

Soon will be listed here.

Abstract

The WW domain-containing oxidoreductase (WWOX), widely expressed in human tissues, is considered as a tumor suppressor gene and plays an important role in the incidence and progression of human cancer, HCC included. This study was to investigate the correlation between single nucleotide polymorphisms (SNPs) of the WWOX gene and the prognosis of hepatocellular carcinoma (HCC) patients. After a total of 152 HCC patients were recruited, 8 cases with tumor recurrence within 2-years after operation and 8 cases without recurrence were selected randomly for SNP genotyping and screening using Affymetrix Array 6.0. And then we confirmed candidate SNPs in the remaining 136 patients by time-of-flight mass spectrometry (TOF-MS). In total, 32 SNPs were screened and identified as candidate SNPs with one SNP in particular, (rs9926344), being further verified to be valuable. We found that AA+AG genotype and A allele of WWOX rs9926344 were significantly associated with recurrent risk of HCC (p=0.002 and p=0.001, respectively). The Kaplan-Meier curve showed that patients carrying rs9926344 AA +AG genotype had poor RFS (=0.004) and OS (=0.005) compared to those carrying GG genotypes. The multivariate COX regression analysis showed that the AA+AG genotype were an independent prognostic factor for tumor recurrence (HR 1.787, 95% CI 1.042-3.064, =0.035). Furthermore, IHC analysis showed that the WWOX protein down-regulation is more frequent in patients with AG genotype compared to those with GG genotype (=0.023). Our findings indicate that WWOX rs9926344 polymorphism is positively correlated with tumor recurrence and can be used as an independent prognostic marker for HCC patients after operation.

Citing Articles

Novel Hydrogel-Mediated Lentiviral Gene Delivery via Intravesical Administration for Bladder Cancer Treatment.

Liu C, Chen P, Lin K, Cheng Y, Chang L Pharmaceutics. 2025; 17(2).

PMID: 40006511 PMC: 11858974. DOI: 10.3390/pharmaceutics17020143.

WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy.

Liu S, Yang S, Xu M, Zhou Q, Weng J, Hu Z J Immunother Cancer. 2024; 12(11).

PMID: 39500530 PMC: 11552608. DOI: 10.1136/jitc-2024-010422.

Polymorphisms as Predictors of the Biochemical Recurrence of Localized Prostate Cancer after Radical Prostatectomy.

Lin C, Wang C, Wang S, Yang C, Li J, Chen C Int J Med Sci. 2023; 20(7):969-975.

PMID: 37324196 PMC: 10266044. DOI: 10.7150/ijms.84364.

Child-Pugh Score and -rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib.

Huang P, Yu J, Chu Y, Lin Y, Yeh C J Clin Med. 2022; 11(9).

PMID: 35566676 PMC: 9105641. DOI: 10.3390/jcm11092550.

Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.

Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D J Pers Med. 2022; 12(2).

PMID: 35207638 PMC: 8879044. DOI: 10.3390/jpm12020149.

References

Lo J, Chou Y, Lai F, Hsu L . Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Exp Biol Med (Maywood). 2015; 240(3):383-91. PMC: 4935227. DOI: 10.1177/1535370214566747. View

Lin W, Hsu C, Yeh C, Chen Y, Chang M, Liang K . Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2017; 14(2):e54-e63. DOI: 10.1111/ajco.12745. View

Paige A, Taylor K, Taylor C, Hillier S, Farrington S, Scott D . WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A. 2001; 98(20):11417-22. PMC: 58744. DOI: 10.1073/pnas.191175898. View

Bednarek A, Laflin K, Daniel R, Liao Q, Hawkins K, Aldaz C . WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 2000; 60(8):2140-5. View

Lee H, Cheng H, Liu Y, Chou M, Yang S, Chou Y . Functional genetic variant of WW domain-containing oxidoreductase (WWOX) gene is associated with hepatocellular carcinoma risk. PLoS One. 2017; 12(4):e0176141. PMC: 5398630. DOI: 10.1371/journal.pone.0176141. View

Li G, Sun L, Mu Z, Huang Y, Fu C, Hu B . Ectopic WWOX Expression Inhibits Growth of 5637 Bladder Cancer Cell In Vitro and In Vivo. Cell Biochem Biophys. 2016; 73(2):417-425. DOI: 10.1007/s12013-015-0654-0. View

Sun W, Dou J, Zhang L, Qiao L, Shen N, Gao W . Expression of CD133, E-cadherin and WWOX in colorectal cancer and related analysis. Pak J Med Sci. 2017; 33(2):425-429. PMC: 5432716. DOI: 10.12669/pjms.332.11687. View

Aqeilan R, Abu-Remaileh M, Abu-Odeh M . The common fragile site FRA16D gene product WWOX: roles in tumor suppression and genomic stability. Cell Mol Life Sci. 2014; 71(23):4589-99. PMC: 11113097. DOI: 10.1007/s00018-014-1724-y. View

Guo W, Dong Z, Dong Y, Guo Y, Kuang G, Yang Z . Genetic and epigenetic alterations of WWOX in the development of gastric cardia adenocarcinoma. Environ Mol Mutagen. 2012; 54(2):112-23. DOI: 10.1002/em.21748. View

10.

Chang N, Doherty J, Ensign A, Schultz L, Hsu L, Hong Q . WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem. 2005; 280(52):43100-8. DOI: 10.1074/jbc.M505590200. View

11.

Hong Q, Hsu L, Schultz L, Pratt N, Mattison J, Chang N . Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol Biol. 2007; 8:50. PMC: 1904229. DOI: 10.1186/1471-2199-8-50. View

12.

Gonzalez-Garay M, McGuire A, Pereira S, Caskey C . Personalized genomic disease risk of volunteers. Proc Natl Acad Sci U S A. 2013; 110(42):16957-62. PMC: 3801013. DOI: 10.1073/pnas.1315934110. View

13.

Hsu L, Hong Q, Schultz L, Kuo E, Lin S, Lee M . Zfra is an inhibitor of Bcl-2 expression and cytochrome c release from the mitochondria. Cell Signal. 2008; 20(7):1303-12. DOI: 10.1016/j.cellsig.2008.02.018. View

14.

Choo A, OKeefe L, Lee C, Gregory S, Shaukat Z, Colella A . Tumor suppressor WWOX moderates the mitochondrial respiratory complex. Genes Chromosomes Cancer. 2015; 54(12):745-61. DOI: 10.1002/gcc.22286. View

15.

Abu-Remaileh M, Joy-Dodson E, Schueler-Furman O, Aqeilan R . Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells. J Biol Chem. 2015; 290(52):30728-35. PMC: 4692203. DOI: 10.1074/jbc.R115.676346. View

16.

Wen J, Xu Z, Li J, Zhang Y, Fan W, Wang Y . Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget. 2017; 8(37):60917-60932. PMC: 5617394. DOI: 10.18632/oncotarget.17126. View

17.

Liu W, Tian T, Liu L, Du J, Gu Y, Qin N . A functional SNP rs1892901 in FOSL1 is associated with gastric cancer in Chinese population. Sci Rep. 2017; 7:41737. PMC: 5294397. DOI: 10.1038/srep41737. View

18.

Lien M, Lin C, Tsai H, Chen Y, Tsai M, Hua C . Impact of CCL4 gene polymorphisms and environmental factors on oral cancer development and clinical characteristics. Oncotarget. 2017; 8(19):31424-31434. PMC: 5458219. DOI: 10.18632/oncotarget.15615. View

19.

Gluer A, Cocco N, Laurence J, Johnston E, Hollands M, Pleass H . Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012; 14(5):285-90. PMC: 3384847. DOI: 10.1111/j.1477-2574.2012.00446.x. View

20.

Cancemi L, Romei C, Bertocchi S, Tarrini G, Spitaleri I, Cipollini M . Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. Int J Cancer. 2011; 129(12):2816-24. DOI: 10.1002/ijc.25937. View